Plasma-Activated Air Mediates Plasmid DNA Delivery In Vivo

Chelsea M. Edelblute  
*Old Dominion University*

Loree C. Heller  
*Old Dominion University*, lheller@odu.edu

Muhammad A. Malik  
*Old Dominion University*, mmalik@odu.edu

Anna Bulysheva  
*Old Dominion University*, abulyshe@odu.edu

Richard Heller  
*Old Dominion University*, rheller@odu.edu

Follow this and additional works at: https://digitalcommons.odu.edu/bioelectrics_pubs

Part of the Genetics and Genomics Commons

**Original Publication Citation**
Edelblute, C. M., Heller, L. C., Malik, M. A., Bulysheva, A., & Heller, R. (2016). Plasma-activated air mediates plasmid DNA delivery *in vivo*. *Molecular Therapy — Methods & Clinical Development*, 3, 16028. doi: 10.1038/mtm.2016.28

This Article is brought to you for free and open access by the Frank Reidy Research Center for Bioelectrics at ODU Digital Commons. It has been accepted for inclusion in Bioelectrics Publications by an authorized administrator of ODU Digital Commons. For more information, please contact digitalcommons@odu.edu.
Plasma-activated air (PAA) provides a noncontact DNA transfer platform. In the current study, PAA was used for the delivery of plasmid DNA in a 3D human skin model, as well as in vivo. Delivery of plasmid DNA encoding luciferase to recellularized dermal constructs was enhanced, resulting in a fourfold increase in luciferase expression over 120 hours compared to injection only (P < 0.05). Delivery of plasmid DNA encoding green fluorescent protein (GFP) was confirmed in the epidermal layers of the construct. In vivo experiments were performed in BALB/c mice, with skin as the delivery target. PAA exposure significantly enhanced luciferase expression levels 460-fold in exposed sites compared to levels obtained from the injection of plasmid DNA alone (P < 0.001). Expression levels were enhanced when the plasma reactor was positioned more distant from the injection site. Delivery of plasmid DNA encoding GFP to mouse skin was confirmed by immunostaining, where a 3-minute exposure at a 10 mm distance displayed delivery distribution deep within the dermal layers compared to an exposure at 3 mm where GFP expression was localized within the epidermis. Our findings suggest PAA-mediated delivery warrants further exploration as an alternative approach for DNA transfer for skin targets.

Molecular Therapy — Methods & Clinical Development (2016) 3, 16028; doi:10.1038/mtm.2016.28; published online 13 April 2016

INTRODUCTION
Plasma is a partially ionized gas generated by high-voltage electrical discharges in atmospheric pressure air. In a thermal plasma, temperature of all the particles are nearly equal and high and there is thermal equilibrium.1,2 Conversely, nonthermal or cold plasmas are not at thermal equilibrium, and only a small percentage of the total gas molecules are charged. As a result, a minimal amount of heat is generated. Cold plasmas are produced when strong applied electric fields accelerate free electrons supplied from the input gas.1 Noble gases (i.e., helium or argon1-4), nitrogenated or oxygenated mixtures,7,8 or ambient air9,10 can be used as the working gas. These systems have shown efficacy in clinical applications 11,12 including facilitating transfer disperses on the target site.

Plasma is a partially ionized gas generated by high-voltage electrical discharges in atmospheric pressure air. In a thermal plasma, temperature of all the particles are nearly equal and high and there is thermal equilibrium.1,2 Conversely, nonthermal or cold plasmas are not at thermal equilibrium, and only a small percentage of the total gas molecules are charged. As a result, a minimal amount of heat is generated. Cold plasmas are produced when strong applied electric fields accelerate free electrons supplied from the input gas.1 Noble gases (i.e., helium or argon1-4), nitrogenated or oxygenated mixtures,7,8 or ambient air9,10 can be used as the working gas. These systems have shown efficacy in clinical applications 11,12 including facilitating transfer disperses on the target site.

In the current study, PAA was used for the delivery of plasmid DNA in a 3D human skin model, as well as in vivo. Delivery of plasmid DNA encoding luciferase to recellularized dermal constructs was enhanced, resulting in a fourfold increase in luciferase expression over 120 hours compared to injection only (P < 0.05). Delivery of plasmid DNA encoding green fluorescent protein (GFP) was confirmed in the epidermal layers of the construct. In vivo experiments were performed in BALB/c mice, with skin as the delivery target. PAA exposure significantly enhanced luciferase expression levels 460-fold in exposed sites compared to levels obtained from the injection of plasmid DNA alone (P < 0.001). Expression levels were enhanced when the plasma reactor was positioned more distant from the injection site. Delivery of plasmid DNA encoding GFP to mouse skin was confirmed by immunostaining, where a 3-minute exposure at a 10 mm distance displayed delivery distribution deep within the dermal layers compared to an exposure at 3 mm where GFP expression was localized within the epidermis. Our findings suggest PAA-mediated delivery warrants further exploration as an alternative approach for DNA transfer for skin targets.

Molecular Therapy — Methods & Clinical Development (2016) 3, 16028; doi:10.1038/mtm.2016.28; published online 13 April 2016

INTRODUCTION
Plasma is a partially ionized gas generated by high-voltage electrical discharges in atmospheric pressure air. In a thermal plasma, temperature of all the particles are nearly equal and high and there is thermal equilibrium.1,2 Conversely, nonthermal or cold plasmas are not at thermal equilibrium, and only a small percentage of the total gas molecules are charged. As a result, a minimal amount of heat is generated. Cold plasmas are produced when strong applied electric fields accelerate free electrons supplied from the input gas.1 Noble gases (i.e., helium or argon1-4), nitrogenated or oxygenated mixtures,7,8 or ambient air9,10 can be used as the working gas. These systems have shown efficacy in clinical applications 11,12 including bacterial inactivation,13-15 dentistry,14,17 wound healing,4 blood coagulation,16 dermatology,19 providing a significant effect on the order of seconds or minutes. Moreover, the bulk of particles produced from cold plasmas are close to room temperature, making them safe for use on heat-sensitive surfaces, such as living tissue.20

Physical methods of DNA transfer, including electrotreatment,21-26 sonoporation,27 and pressure-based platforms such as hydrodynamic therapy28 and mechanical massage29,30 are well tolerated in living tissues.31,32 Though effective, physical delivery approaches can be considered invasive. A noncontact apparatus would minimize local discomfort at the exposure site. Cold plasma in the form of a high current version of the sliding discharge can be administered without direct contact, where neither the plasma reactor nor the plasma afterglow touches the target surface.33-35 Instead, the plasma-activated air (PAA) facilitating transfer disperses on the target site.

Utilizing helium-based plasma for DNA transfer has been reported in vitro and in vivo.36,37 The therapeutic aims of these studies included delivery of a DNA vaccine to elicit an antigen-specific humoral immune response,38 and an antitumoral therapy where plasmid DNA encoding the cytokine IL-28 was delivered.39 While efficient delivery of plasmid DNA was achieved, alternative types of plasma systems may be advantageous. The device used in the current work operates using ambient air as the input gas for plasma generation. This eliminates the incorporation of an external gas tank, making the footprint for the entire system smaller and more portable.

In the current work, we tested PAA-mediated DNA transfer in a human skin model and an animal model to determine if this platform would deliver plasmid DNA to skin. We previously demonstrated utilizing PAA as a DNA transfer method in vitro.40 Recellularized human dermis was used as a preliminary substrate before progressing to a mouse model. For in vivo testing, an animal model using BALB/c mice, a strain typically used for vaccine testing, was employed to determine the potential use of PAA as a noncontact DNA transfer method to a living tissue. Plasmid DNA encoding the reporter genes luciferase and green fluorescent protein (GFP) were used to determine both the kinetics and distribution of PAA-mediated DNA delivery.

RESULTS
Twenty-four hours following a 3-minute PAA exposure, luciferase expression in the recellularized dermal constructs peaked (Figure 1). Average total flux results for a 3-minute exposure were $8.44 \times 10^5$ photons/second (p/s) after 72 hours. This was significant compared to an intradermal injection of gWizLuc alone (P < 0.05). A significant increase in luciferase expression was also observed 120 hours post-PAA exposure (P < 0.05).
were higher in the PAA-exposed sites relative to injection only for the entire 4-week follow-up period (Figure 3). Quantitative expression results obtained on day 7 were \(9.75 \times 10^6\) and \(5.47 \times 10^7\) p/s for a 3-minute PAA delivery, at a 3 and 10 mm distance respectively. This represents an 82- and 460-fold difference for a 3 mm and 10 mm PAA delivery distance with respect to expression levels obtained from injection only \((P < 0.001)\). Peak luciferase expression was achieved 17 days following exposure at a 10 mm distance from the injection site where the average total flux was \(5.55 \times 10^7\) p/s \((P < 0.05)\). Though expression levels tended to be higher in sites receiving PAA at a 10 mm distance, this result was not significant compared to PAA delivered at a 3 mm distance.

Fluorescence images of sectioned mouse skin samples receiving PAA exposure indicate positive GFP signal observed on the TRITC channel after immunostaining (Figure 4). When these images are merged with corresponding micrographs on the 4', 6-diamidino-2-phenylindole dihydrochloride channel, it is clear that GFP expression is present in the cytoplasm of epithelial cells. PAA exposure at a further distance of 10 mm (Figure 4j–l) appears to enhance GFP expression compared to exposure at a 3 mm distance (Figure 4g–i). Adipocytes in the field of view display auto fluorescence, even in the control receiving no plasmid DNA or PAA exposure, suggesting this is not a positive GFP signal (Figure 4a–c). Expression extends from the epidermal to dermal layers in the samples receiving PAA exposure at a distance of 10 versus 3 mm, suggesting an increased exposure distance delivers the plasmid DNA to cells deeper within the tissue. Positive GFP signal above background was not observed in the injection only control (Figure 4d–f).

### DISCUSSION

The current study evaluated PAA-mediated plasmid DNA delivery in a 3D human skin model, as well as in vivo. We previously reported the use of PAA for DNA transfer in vitro. Initially, recellularized human dermal constructs were employed as an alternative delivery substrate before moving to an animal model. The recellularized dermal constructs provided a 3D structure more akin to human skin, and superior to existing in vitro skin models. Three weeks grown at an air-liquid interface provided sufficient time for the epithelial cells to differentiate, allowing for a functional epithelium to form in culture.

Three minutes of PAA exposure enhanced the delivery of gWizLuc to recellularized dermal constructs compared to an injection only control. No significant drop in viability of the constructs as a consequence to PAA exposure was observed. Furthermore, PAA-mediated delivery of gWizGFP to recellularized dermal constructs was confirmed by observing positive GFP expression in the upper epidermal layers and within the base of a hair follicle. No positive signal above background was observed in the injection only control.

An in vivo murine model in BALB/c mice was used to test PAA-mediated plasmid DNA transfer to living tissue. We first determined the heat generation from this approach, as a nonthermal platform would be ideal for reducing the damaging effects of excess skin-heating. Temperature measurements were taken at the shorter exposure distance of 3 mm, the closest tested distance from the plasma source, where the generation of heat would likely be highest. No significant changes in temperature at the exposed site following PAA exposure were recorded, suggesting heat does not facilitate DNA transfer in this approach.

Quantitative results measured over 28 days displayed luciferase levels 460-fold greater in PAA-exposed mouse skin sites than levels obtained from the injection of gWizLuc alone. Increasing

---

**Table 1** Metabolic activity in recellularized dermis post PAA-exposure

| Time postexposure (hours) | Group          | 1       | 24      | 48       |
|---------------------------|----------------|---------|---------|----------|
| Injection only            | 83.75 ± 6.87\% | 86.13 ± 1.90\% | 84.02 ± 12.26\% |
| Three-minute PAA          | 90.44 ± 7.18\% | 88.97 ± 2.67\% | 74.47 ± 6.02\% |

PrestoBlue cell reagent measuring metabolic activity was used for viability analysis. The experimental group is a PAA exposure of 3 minutes after intradermal injection of plasmid DNA. Mean % viability ± standard error of the mean, \( n = 3 \). Results are not significant with respect to samples receiving only the plasmid DNA injection without PAA exposure.

PAA, plasma-activated air.
the distance between the plasma device and the target surface enhanced expression levels. This result further confirms that heat does not facilitate transfer of plasmid DNA in this approach. Gross observation and monitoring of the mice after plasma exposure revealed no apparent levels of discomfort or skin deformations at the delivery site. The animals maintained activity and consumption levels for the entire monitoring period.

PAA-mediated delivery of gWizGFP to mouse skin was confirmed by analyzing GFP expression. Immunostaining of the harvested tissue indicated that delivery of gWizGFP extended beyond the lower epidermis with an exposure at a distance of 10 mm, while GFP expression was localized in the upper epidermis in the group receiving an exposure at the shorter distance of 3 mm.

We previously confirmed the presence of ozone and NO2 in the plasma-activated gas under operating parameters. It is probable that the generation of diluted reactive species in the PAA assists plasmid DNA delivery. Both ozone and NO2 effect cellular membranes, and the effects are enhanced with increasing product amounts. Viability results suggest the concentrations of these species in the PAA are minimally toxic. The mechanism of PAA-mediated delivery has not yet been elucidated, but it is the consensus that plasma composition alone, i.e., reactive oxygen species and reactive nitrogen species production is not enough to explain plasma-induced effects. Disruption of E-cadherin-based cell junctions and downregulation of E-cadherin mRNA was reported following nonthermal plasma exposure, leading to a reversible decrease in barrier function. In particular, one group used a nonmetallic electric field probe to measure the electric field at the plasma plume and within plasma targets, showing that an electric field strength up to 1 kV/cm was achieved with the Plasma Gun at a depth up to several millimeters. These field strengths suggest electropermeabilization is happening with plasma exposure, and could allow for a plasmid to be driven through transient membrane holes.

Table 2  Skin surface temperature following PAA exposure

| Group                      | Temperature (°C) |
|----------------------------|------------------|
| Before PAA exposure        | 26.6 ± 0.1       |
| After 3 minutes PAA        | 26.1 ± 0.6       |

Surface temperature of the exposed region was measured using an infrared probe. Measurements were taken immediately before and after a 3-minute PAA treatment at a distance of 3 mm. Mean ± standard error of the mean, n = 4. PAA, plasma-activated air.

Figure 2  GFP expression in recellularized dermal constructs. An immunostaining protocol using a goat polyclonal anti-GFP antibody fluorescein isothiocyanate (FITC) (ab6662, Abcam, Littleton, CO) as the primary antibody was performed on fixed cryosectioned constructs. 4',6-Diamidino-2-phenylindole dihydrochloride (DAPI) nuclear stain was used to determine location of expression. (a–c) Intradermal injection of gWizGFP only control on DAPI (left) and FITC (center) channels, overlaid image in right column. (d–f) Constructs exposed to PAA for 3 minutes after intradermal injection of gWizGFP. n = 3. Scale bar = 50.0 μm. 200×.

Figure 3  Plasma-activated air (PAA)-mediated gWizLuc delivery in BALB/c mice. Luciferase expression was monitored in total flux (photons/second) over a 28-day period following PAA exposure. Treatment parameters included a 3-minute PAA exposure at either a 3 or 10 mm distance from the intradermal injection site. Results were compared to levels achieved from injection only controls. Mean ± standard error of the mean, n = 4 injection only, n = 8 per experimental group. *P < 0.05; **P < 0.01; ***P < 0.001.
The proposed mechanism in the current approach is electrophysical, i.e., when sufficient electrostatic charge is deposited on the cell membrane it causes outward electrostatic stress that induces electroporation and subsequent entry of plasmid DNA into the cell. Plasma-induced electrostatic stress can be strong enough to rupture the membrane after plasma exposure, e.g., bacterial decontamination, but the lower field strength used in this study avoids this effect. Plasma operating parameters, including the applied voltage, remained constant in this study where only the distance between the plasma reactor and the target site was adjusted. The size of the port where the PAA exits compared to the size of the intradermal plasmid DNA injection is much smaller, suggesting charge dispersion across a relatively larger area would be necessary for transfer.

We were able to achieve this by increasing the distance between the plasma reactor and the skin. Based on our results in vivo, the increased air flow dispersal permitted by a 10 mm distance versus a 3 mm distance to the target site allows for a more widespread accumulation of electrostatic charge, enhancing plasmid DNA delivery and resulting in higher expression levels and deeper expression distribution within the PAA-exposed tissue.

The novel nonthermal plasma reactor presented provides effective plasmid DNA delivery in vivo, with skin as the target tissue. Though a significant increase in expression is achieved, compared to some other DNA transfer methods expression levels are lower. Current nonviral methods have their disadvantages. Direct injection is the most widely used nonviral DNA transfer platform, yet delivery...
levels are poor and expression is localized solely at the site of injection. Sonoporation, using ultrasonic waves to deliver microbubble-contained compounds is limited by proximal organs and bones. Mechanical massage, a noninvasive pressure-based gene delivery approach, yields peak expression 6 hours after the plasmid DNA is introduced. This level drops to baseline soon after, and repeat injections and massage must be administered to achieve the same effect. PAA-mediated transfer shows promise for drug and gene therapy, though temporary pain was reported by patients after pulse application. Expression levels achieved with electrotransfer are approximately eightfold higher than what we achieved with PAA in this study. However, there was no observable tissue damage from PAA exposure, as is a concern with electrotransfer at higher field strengths. Compared to all of these aforementioned methods, PAA does not require any direct electrode contact with the target to facilitate DNA transfer. We therefore emphasize that PAA would make a good noncontact alternative if multiple treatments are necessary, or to minimize patient discomfort.

This plasma system generating PAA is portable and scalable to accommodate delivery to larger areas. The level of expression achieved with PAA may be advantageous for some therapies where overexpression of the transgene could lead to toxic effects. Our work did not systematically determine parameters needed for controlled expression, a critical aspect for therapeutic development. These studies could augment the potential use of cold plasmas in healthcare settings. Nonetheless, due to its noncontact application this method would be attractive to both patients and healthcare professionals. Certain cohorts of patients including the young and elderly, or those with diabetes or cancer are more susceptible to infection and other treatment complications, and would assume a lower risk using non-invasive delivery methods. In the future, histological analysis will be necessary to determine the local impact of PAA exposure on tissue. Our results prove PAA can be used to deliver plasmid DNA in vivo with skin as the delivery target, providing both the kinetic and distribution expression patterns achieved with this platform at the current operating parameters. PAA-mediated delivery warrants further exploration as an alternative or supplemental DNA transfer approach.

MATERIALS AND METHODS

Plasma system

The reactor has been previously described. Briefly, it consists of two parallel glass dielectric plates; separated by spacers, with aluminum foil electrodes placed perpendicular to the applied air flow, creating an inter-electrode gap of 2.0 cm in the discharge chamber. Sliding plasma discharges were formed at solid-gas interface along the glass dielectric layer in the discharge chamber measuring 2.6 ± 0.03 cm. For operating parameters used in this study, the high-voltage electrode was pulsed biased positively by applying a pulsed voltage of 12 ± 0.5 kV peak voltage, 50 ns rise time, 100 ns duration (full width at half maximum) at a repetition rate of 500 Hz. Ambient air supplied at a flow rate of 5 SLM from a Whisper AP 300 fish tank air pump was used as the input gas.

For PAA-mediated plasmid DNA delivery in the animal model, the exit slit of plasma reactor was oriented longitudinally above the injection site, creating two equal hemispheres on either side of the reactor’s outer limits (Figure 5). The same set-up position was used for PAA-mediated plasmid DNA delivery to the human skin model.

Plasmids

Endotoxin-free plasmids gWizLuc and gWizGFP were commercially prepared to ensure quality (Aldenvon, Fargo, ND) and suspended in sterile injectable saline at 2 mg/mL. For all experiments, 100 µg in a 50 µl volume of respective plasmid DNA was used per experimental or control sample or animal.

Recellularized dermics

The dermal constructs utilized contained three components. DermACELL (LifeNet Health, Virginia Beach, VA) which are decellularized skin grafts, human primary dermal fibroblasts (ATCC, Manassas, VA) and a human Keratinocyte cell line (HaCaT). Fibroblasts were maintained in culture with Dulbecco’s Modified Eagle Medium, 10% fetal bovine serum, 1% penicillin/streptomycin at 37 °C and 5% CO2. HaCaT cells were maintained in culture using both the same media formulations and growth conditions as the fibroblasts. Prior to use, DermaCell grafts were washed in Dulbecco’s phosphate-buffered saline and cut into 12 mm disks using a biopsy punch, then washed twice with Dulbecco’s Modified Eagle Medium.

Recellularizing the dermal constructs was performed using a previously developed and validated protocol. Briefly, the procedure is performed in a 12-well plate. DermaCell is placed in the well and then 1 x 10⁵ fibroblasts/disk were placed on the reticular face of the dermis. After one week of growth, 1.5 x 10⁴ HaCaT cells/disk were added to the papillary face of the graft (disk is turned over). Following overnight incubation, the grafts were moved to the upper chamber of Transwell Permeable Supports (Corning Incorporated, Life Sciences, Tewksbury, MA). The bottom well was filled with media, while the top well was left void of media. Recellularized dermics was cultured for 3 weeks with daily media changes before PAA-mediated plasmid DNA delivery.

Viability analysis

PrestoBlue Cell viability assay (Molecular Probes, Carlsbad, CA) was used to measure the metabolic activity of recellularized dermics following PAA exposure. Briefly, the constructs were incubated with the PrestoBlue reagent for two hours, after which 850 µl of each well was transferred in duplicate to a 24-well plate. Fluorescence was recorded by setting excitation and emission at 560 and 590 nm respectively. Duplicate experimental wells were averaged. Control wells containing reagent only were averaged and subtracted as background from the fluorescence value of each experimental well. Measurements were taken 2, 24, and 48 hours postexposure. Percent viability was determined by dividing the fluorescence intensity of samples
injected with plasmid DNA alone and PAA-exposed constructs by controls that were not injected or exposed to PAA at each respective time point.

Animal model
A murine model using BALB/c mice was employed. All procedures were approved by the Old Dominion University Institutional Animal Care and Use Committee. A total of 20 female 8-week-old BALB/c mice of the same age were used for this study. Mice were anesthetized during all deliveries. To anesthetize, animals were placed in an induction chamber infused with a mixture of 3–5% isoflurane and 97% oxygen gas for several minutes. After anesthetized, mice were fitted with a standard rodent mask supplied with 2–3% isoflurane and oxygen to maintain a surgical plane of anesthesia. After exposure, each mouse was monitored continuously until recovered from anesthesia, as indicated by their ability to maintain sternal recumbency and to exhibit purposeful movement.

Temperature measurements
An infrared probe (NationSkan der California, Anaheim, CA) was used for recording temperature measurements at the mouse skin surface of each exposed site. The infrared probe was not used while the plasma reactor was in operation. Instead, the temperature was measured immediately before and after application of a 3-minute exposure of PAA at a 3 mm distance.

PAA exposure
Recellularized dermal constructs cultured for 3 weeks were split into three groups. One hundred micrograms of gWiz-LUC was intradermally injected in a volume of 50 µl (2 mg/ml) to the constructs. The experimental group was exposed to 3 minutes of PAA at a distance of 10 mm immediately following injection of plasmid DNA. An injection only control and a control without injection of plasmid DNA were included for comparison.

For the in vivo study, each mouse received two experimental sites, one each on opposing flanks. gWizzLuc was injected intradermally to shaved flanks in a 50 µl volume (100 µg total, 2 mg/ml) immediately before PAA exposure. The plasma reactor was placed longitudinally above the injection site at a constant distance of either 3 or 10 mm. Operating parameters were set as previously described. An exposure duration of 3 minutes was tested, where the reactor remained stationary during the entire exposure.

Luciferase expression
Luciferase gene expression in the recellularized dermal constructs was measured 24, 48, 72, and 120 hours after PAA exposure. Old media was removed and replaced with fresh media containing 150 g/ml Luciferin. Samples were incubated in the dark for 5 minutes and then imaged with a Caliper In Vivo Imaging Spectrum whole body imaging system (PerkinElmer, Waltham, MA). Luciferase expression was quantified as total flux measured in photons per second.

Kinetic luciferase expression in vivo was monitored over a 28-day period using a Caliper In Vivo Imaging Spectrum whole body imaging system (IVIS). For imaging, the animals were anesthetized in the same manner as described for delivery. Anesthesia was maintained in the imaging chamber by use of an anesthesia block supplying five nose cones. Once the animals were anesthetized, an intraperitoneal injection of 200 µl D-luciferin at a concentration of 15 mg/ml, was given. The mice were imaged 5 minutes after the luciferin injection, representing peak signal detection.

Each mouse received one specific delivery parameter on both of its flanks. In addition, the opposing flank was blocked during PAA exposure using a surgical sheet, allowing for sole exposure of the injection site. Kinetic luciferase expression in BALB/c mice following PAA exposure was measured nine times over a 28-day period. Images were taken on days 1, 2, 4, 7, 9, 14, 17, 21, and 28 post-PAA exposures. A region of interest was drawn around the sites with positive signal. An area of unexposed skin was also measured and subtracted as a background measurement from total flux values. The average of each experimental condition was determined ± standard error of the mean.

CONFLICT OF INTEREST
The authors declared no conflict of interest.

ACKNOWLEDGMENTS
The authors thank Gary Walters of LifeNet Health, Virginia Beach, VA for gifting DermCELL™ human allograft tissue with research consent.
